Company history

iOmx has been founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016. The Company has attracted leading international life science investors and closed a EUR 40 million Series A financing round only a few months after its inception. The proceeds will be used to advance proprietary product candidates up to initial clinical proof-of-concept.

Management

Apollon Papadimitriou
Apollon is the Chief Executive Officer. Apollon acted as Chief Development Officer at iOmx from 2017 until mid of 2019. He has a long-standing track record in biotherapeutics development and has significantly contributed to the development and launch of many biologics products. Before joining iOmx in 2017, he acted as Global Head Large Molecule Bioanalytical R&D and Pharmaceutical Sciences Site Head at Roche Innovation Center Munich. During his career at Roche, starting in 1997, Apollon held several leadership positions in Biologics R&D within Pharma Research and Early Development and has been a key contributor to the foundation, build-up and evolution of Roche´s global large molecule research organization and pipeline. Apollon is a biologist by training and earned his PhD in Biochemistry in 1995 from the Julius-Maximilians-University of Würzburg, Germany. After a post-doctorate at the Institute for Experimental Cancer Research in Freiburg, Germany, he started his industrial career at Boehringer Mannheim in 1996 as a Senior Scientist in Biotechnology Research.
read more
Nisit Khandelwal
Nisit is the scientific co-founder of iOmx and serves as its Senior Vice-President, Research. Prior to joining iOmx, Nisit served as PI for a joint research project between the German Cancer Research Center and Bayer Health Care from 2014-2016. He is a research-driven entrepreneur with a strong focus on target discovery and early-stage drug development in the field of cancer immunotherapy. He is the lead inventor on a portfolio of patents and author of high-impact scientific publications. Nisit completed his undergraduate degree in Biotechnology from Vellore Institute of Technology in India and obtained his Masters degree in Biomedical Sciences from the University of Edinburgh in U.K. In 2011, he joined the laboratory of Prof. Dr. Philipp Beckhove at the German Cancer Research Center (DKFZ) in Heidelberg, Germany as a Helmholtz Scholar for his doctoral thesis on high-throughput identification of novel immune-checkpoint molecules on tumors.
read more
Marcus Irsfeld
Marcus is the Chief Financial Officer. He has a long-standing track record in this position either as employee or freelancer in the life science industry. Over the last years, he has been supporting several biotech and MedTech companies in different maturity stages. In 2001, he started his career in the life science industry as CFO of ProCorde GmbH which merged with Trigen in 2006. He finally took over the responsibility for the whole Trigen Group as the sole member of the executive board of Trigen Holdings AG. Before joining ProCorde, Marcus worked in different industries, including financial controller in a German Chinese joint venture in the province Shandong in China. Marcus holds a degree in Business Administration from the University in Münster, Germany. Marcus was co-founder and CFO of Averitas Pharma Inc. (NJ) which was successfully sold to Gruenenthal.
read more

Supervisory Board

Henrijette Richter, Chairperson of the Board
Henrijette Richter is Partner at Sofinnova Partners, Paris. She joined in 2014 from Novo Seeds (part of Novo A/S) where she was involved in the establishment of the group in 2007. While at Novo Seeds Henrijette was instrumental in the creation, financing and building of companies such as Cytoguide, Orphazyme, Avilex Pharma, EpiTherapeutics (sold to Gilead) and Lysogene. Henrijette is a scientist by training and started her career at Novo Nordisk conducting her PhD in the area of obesity and GH signalling. Before joining Sunstone Capital in 2004, Henrijette was a postdoctoral fellow at the MIT Center for Cancer Research (MA). Henrijette is a member of WITH (Women innovating together in Healthcare) and she is a board member of Asceneuron (CH).
read more
Tony Rosenberg
Tony Rosenberg joined MPM in 2015. Prior to joining MPM, Tony served as Global Head, M&A and Licensing (Corporate) for Novartis (NVS), based in Basel, Switzerland. In this role Tony oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics. Tony is a Board member at Clinical Ink, Radius and TriNetX and is a former board member at Idenix, all MPM portfolio companies. Tony joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group. Tony has a Bachelor of Science degree in Biological Sciences from the University of Leicester and a Masters of Science in Physiology from the University of London.
read more
Patrick A. Baeuerle
Patrick A. Baeuerle, Ph.D., joined MPM in 2015. Patrick is responsible for the development of BiTE antibody Blincyto® (blinatumomab; AMG 103) which was approved within three months by the US FDA for therapy of relapsed/refractory acute lymphoblastic leukemia. He also spearheaded the development of the BiTE technology, the industry- leading T-cell engaging antibody platform.

Prior to joining MPM, Patrick served as Vice President, Research, and General Manager, Amgen Research (Munich) GmbH, where he oversaw translational science as well as BiTE development. From 1998-2012, Patrick served as Chief Scientific Officer for Micromet, Inc., and earlier oversaw drug discovery at Tularik Inc., a publicly traded biotechnology company acquired by Amgen (AMGN). He also served as Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, and did seminal research on transcription factor NF-kappaB at the Gene Center in Martinsried, Germany.

Patrick was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997). A recipient of numerous awards, he holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.
read more
Philipp Beckhove
Philipp Beckhove, M.D., Ph.D., is the co-founder of iOmx Therapeutics and is currently the Director of Regensburg Center of Interventional Immunology (RCI) at University of Regensburg, Germany. As tumor immunologist, Philipp's scientific work focuses on translating basic immunological research into new therapies for oncology. Prior to joining RCI in 2015, Philipp headed the Division of Translational Immunology at the German Cancer Research Center in Heidelberg, Germany from 2011-2015. He specialized in internal medicine at the University of Heidelberg in 2009. As of 2009, Philipp also holds an adjunct Associate Professorship of Immunotherapy at the Comprehensive Cancer Center, Northwestern University, Chicago, U.S.A.
read more

Scientific advisory

iOmx will be supported by a high-profile team of reputed international scientists in the field of oncology, immunotherapy and clinical drug development who will serve on its Scientific Advisory Board (to be announced soon).

Philipp Beckhove, Chair of the Scientific Board
Philipp Beckhove, M.D., Ph.D., is the Director of Regensburg Center of Interventional Immunology (RCI) at University of Regensburg, Germany. As tumor immunologist, Philipp's scientific work focuses on translating basic immunological research into new therapies for oncology. Prior to joining RCI in 2015, Philipp headed the Division of Translational Immunology at the German Cancer Research Center in Heidelberg, Germany from 2011-2015. He specialized in internal medicine at the University of Heidelberg in 2009. As of 2009, Philipp also holds an adjunct Associate Professorship of Immunotherapy at the Comprehensive Cancer Center, Northwestern University, Chicago, U.S.A.
read more
Patrick A. Baeuerle
Patrick A. Baeuerle, Ph.D., joined MPM in 2015. Patrick is responsible for the development of BiTE antibody Blincyto® (blinatumomab; AMG 103) which was approved within three months by the US FDA for therapy of relapsed/refractory acute lymphoblastic leukemia. He also spearheaded the development of the BiTE technology, the industry- leading T-cell engaging antibody platform.

Prior to joining MPM, Patrick served as Vice President, Research, and General Manager, Amgen Research (Munich) GmbH, where he oversaw translational science as well as BiTE development. From 1998-2012, Patrick served as Chief Scientific Officer for Micromet, Inc., and earlier oversaw drug discovery at Tularik Inc., a publicly traded biotechnology company acquired by Amgen (AMGN). He also served as Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, and did seminal research on transcription factor NF-kappaB at the Gene Center in Martinsried, Germany.

Patrick was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997). A recipient of numerous awards, he holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.
read more